<?xml version="1.0" encoding="UTF-8"?>
<p id="Par8">Olaparib (Selleck Chemicals, Houston, TX, USA) at different doses was intraperitoneally injected 2Â days before and 5 consecutive days after H1N1 virus challenge. The day of virus challenge was defined as experimental day 1. Oseltamivir (Hoffmann-La Roche, Basel, Switzerland) was administered in a similar manner to olaparib.</p>
